Archers take aim against breast cancer in weekend tournament in Cullman alabamanewscenter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alabamanewscenter.com Daily Mail and Mail on Sunday newspapers.
CT-BHI President Joyce Bray to Receive Alumna Award - Greater Hartford, CT - Recognition by Saint Mary's College Honors Decades of Effective Leadership, Raising Funds for Breast Cancer Research, Education & Support
Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
New technology predicts effectiveness of chemotherapy after one treatment
While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patient s quality of life.
An interdisciplinary team of researchers at Washington University in St. Louis has found that combining data from tumor biomarkers, ultrasound, and ultrasound-guided diffuse optical tomography (DOT) after a patient s first cycle of pre-surgical neoadjuvant chemotherapy provided a highly accurate prediction of how the tumor was responding to the treatment. The results from a clinical trial at Washington University School of Medicine and Barnes-Jewish Hospital were published online in
(0)
Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50
Whole transcriptome analysis confirms that genomic expression profiles from BluePrint ER+ Basal tumors and ER- Basal tumors are very similar, providing clinically actionable information to guide neoadjuvant treatment decisions
FLEX real-world registry to enroll 10,000 patients with breast cancer by end of 2021, with ultimate goal to enroll 30,000 total Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.